Residency · Residency · Anesthesiology

Nitrous Oxide: Benefits, Risks, and the Case For or Against Routine Use

Overview

Nitrous oxide (N2O) is the oldest anesthetic still in clinical use, discovered by Priestley in 1772 and first used in dentistry by Wells in 1844. It is a low-potency inhaled anesthetic with a MAC of 104%, meaning it cannot produce surgical anesthesia alone at atmospheric pressure. It is used as an adjunct to volatile agents or IV agents at concentrations of 50-70%. Its role in modern practice is actively debated due to accumulating evidence of potential harms.

Pharmacology

Physical Properties

Nitrous oxide is a colorless, sweet-smelling gas with a blood-gas partition coefficient of 0.47 (low solubility, yielding rapid onset and offset) and an oil-gas partition coefficient of 1.4 (very low potency). It is not metabolized by the liver and is eliminated unchanged via the lungs; only 0.004% undergoes reductive metabolism in the GI tract.

Mechanism of Action

The primary mechanism is NMDA receptor antagonism. Secondary effects include activation of opioidergic and descending inhibitory pathways, which contribute to its analgesic properties. Unlike volatile agents, N2O has minimal GABA-A receptor activity.

Pharmacokinetics

The rapid onset and offset of N2O reflect its low blood-gas solubility. The concentration effect and second gas effect are clinically relevant at the high concentrations used (50-70%). Rapid washout after discontinuation mandates supplemental O2 to prevent diffusion hypoxia.

Benefits of Nitrous Oxide

Anesthetic Advantages

N2O is MAC-sparing, reducing volatile agent requirement by approximately 50-60% when used at 60-70%. Its rapid onset and offset make it predictable and easily titratable. It provides significant analgesia at sub-anesthetic concentrations (30-50%) and useful anxiolysis, particularly in pediatric and dental settings. Unlike volatile agents, N2O has mild sympathomimetic properties that partially offset myocardial depression, resulting in minimal cardiovascular depression. It does not trigger malignant hyperthermia.

Practical Advantages

N2O is inexpensive, non-irritating to the airways, and carries a long track record of safety. It is useful for inhalational induction in children by speeding induction via the second gas effect. It can also substitute for a portion of volatile agent in patients requiring low-concentration volatiles, such as during neuromonitoring.

Risks and Concerns

Expansion of Closed Gas Spaces

N2O is 34 times more soluble in blood than nitrogen. It diffuses into air-filled spaces faster than nitrogen can diffuse out, causing expansion. This creates absolute contraindications in patients with pneumothorax (which can double in volume in 10 minutes), pneumocephalus (post-craniotomy or posterior fossa procedures), air embolism, bowel obstruction (controversial but may worsen distension), middle ear surgery, and intraocular gas bubbles (SF6 or C3F8 after vitreoretinal surgery — N2O should be avoided for 2-3 months after SF6 and 3 months after C3F8). Relative concerns include prolonged abdominal surgery and tympanoplasty.

Postoperative Nausea and Vomiting (PONV)

N2O consistently increases PONV risk. The ENIGMA trial and subsequent meta-analyses demonstrate an absolute risk increase of approximately 4-10%. The mechanism likely involves stimulation of the chemoreceptor trigger zone, middle ear pressure changes, and bowel distension. For patients at high PONV risk, omitting N2O is a straightforward risk-reduction strategy.

Hematologic Effects

N2O irreversibly oxidizes the cobalt atom in vitamin B12, inactivating methionine synthase. The consequences of methionine synthase inhibition include impaired DNA synthesis (with megaloblastic changes in bone marrow), elevated homocysteine levels (a potential cardiovascular risk), and neurological dysfunction (subacute combined degeneration of the spinal cord with prolonged or repeated exposure). Single short exposures do not produce clinically significant hematologic effects, but prolonged exposure beyond 6 hours or repeated exposures can cause megaloblastic bone marrow changes. Patients with pre-existing B12 or folate deficiency are at higher risk. Historically, chronic occupational exposure has caused neuropathy in dental workers.

ENIGMA and ENIGMA-II Trials

The ENIGMA trial (2007) enrolled 2,050 patients and compared 70% N2O to N2O-free anesthesia. The N2O group had higher wound infection rates and more severe PONV, but no difference in mortality. ENIGMA-II (2014) was larger — 7,112 high-risk patients undergoing major non-cardiac surgery — and found no difference in the primary composite endpoint of death and cardiovascular complications at 30 days. N2O was associated with more PONV and more pulmonary complications (atelectasis). The bottom line: N2O does not increase cardiovascular risk or death in high-risk patients, but it modestly increases PONV and minor pulmonary complications.

Environmental Concerns

N2O is a greenhouse gas with a global warming potential approximately 300 times that of CO2 and also contributes to ozone layer depletion. Operating room waste gas is a meaningful source of environmental N2O, and there is a growing movement to eliminate or capture it for environmental reasons.

Teratogenicity

Animal studies suggest teratogenic potential related to methionine synthase inhibition and DNA synthesis disruption, but no clear evidence of teratogenicity exists in humans at clinical exposures. Many practitioners avoid N2O during the first trimester as a precautionary measure.

Diffusion Hypoxia

Upon discontinuation of N2O, large volumes diffuse from blood into the alveoli, diluting alveolar O2 and CO2 (the Fink effect). Prevention requires administering 100% O2 for 3-5 minutes after N2O discontinuation, and the phenomenon is more significant in patients with compromised respiratory function.

The Debate: Should N2O Still Be Used Routinely?

Arguments For Continued Use

Proponents point to a safety record spanning over 175 years, the ENIGMA-II finding of no increase in major morbidity or mortality, significant MAC reduction allowing lower volatile concentrations, analgesic properties that may reduce opioid requirements, usefulness in specific scenarios (pediatric induction, dental sedation, labor analgesia), and low cost with wide availability.

Arguments Against Routine Use

Critics note the well-established increase in PONV, environmental harm from greenhouse gas emissions and ozone depletion, bone marrow toxicity risk with prolonged use, contraindications in many common surgical scenarios (laparoscopic surgery, neurosurgery, ENT), the availability of modern alternatives (low-solubility volatiles, opioids, TIVA) that make N2O unnecessary for most cases, the limitation of FiO2 to 30-50% when N2O is used at 50-70%, and subtle but real increases in homocysteine levels with potential cardiovascular implications.

Current Practice Trends

N2O use is declining worldwide. Many academic centers have removed it from operating room pipelines. It remains widely used in obstetric units (as Entonox — 50% N2O/50% O2 for labor analgesia), in pediatric dentistry, and in office-based sedation. Individual practice varies significantly.

<image>A medical illustration showing a cross-section of an air-filled body cavity (pneumothorax) with arrows demonstrating the mechanism of nitrous oxide expansion: N2O molecules diffusing into the closed space from blood 34 times faster than nitrogen can diffuse out, resulting in progressive expansion of the gas space. A volume-time graph beside it shows the rate of pneumothorax expansion with and without N2O.</image>

<image>A biochemical pathway diagram showing the interaction of nitrous oxide with vitamin B12 and methionine synthase. The diagram shows: (1) N2O oxidizing the cobalt ion in B12 from Co+ to Co3+, (2) irreversible inactivation of methionine synthase, (3) downstream effects including impaired conversion of homocysteine to methionine, (4) reduced tetrahydrofolate regeneration, and (5) impaired DNA synthesis leading to megaloblastic changes in rapidly dividing cells.</image>

<image>A forest plot summarizing the key outcomes from the ENIGMA-II trial comparing nitrous oxide versus nitrous oxide-free anesthesia: showing odds ratios with 95% confidence intervals for the primary composite endpoint (death and cardiovascular complications), individual components, PONV, wound infection, and pulmonary complications. The plot demonstrates no significant difference for major outcomes but significant increases in PONV with N2O.</image>

Clinical Pearls

N2O has an absolute contraindication in any patient with a closed air-filled space, including pneumothorax, pneumocephalus, bowel obstruction, and recent eye surgery with a gas bubble. Supplemental 100% O2 for at least 3-5 minutes after discontinuing N2O prevents diffusion hypoxia. The MAC-sparing effect is the primary anesthetic advantage, but modern low-solubility agents and opioids can achieve similar goals. ENIGMA-II is the definitive trial: no increase in death or major cardiovascular events, but PONV is consistently higher. For high PONV-risk patients — female, non-smoker, history of motion sickness, postoperative opioids — avoiding N2O is one of the simplest risk-reduction strategies. Always ask about recent eye surgery (vitreoretinal procedures) before using N2O, since SF6 gas may persist for weeks.

References

• Myles PS, et al. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial (ENIGMA). Anesthesiology. 2007;107(2):221-231.
• Myles PS, et al. Nitrous oxide and risk of major adverse cardiovascular events (ENIGMA-II). N Engl J Med. 2014;370:1494-1503.
• Sanders RD, et al. Nitrous oxide in clinical practice. Br J Anaesth. 2008;100:747-757.
• Rappaport BA, et al. Nitrous oxide: outdated or still useful? Anesthesiology. 2019.

Read this lecture as Markdown